MRTX1719 is a potent and selective inhibitor of the protein arginine methyltransferase 5·methylthioadenosine phosphorylase complex (PRMT5·MTA), which serves as a potential selective therapeutic target for tumor intervention.
Navlimetostat is an effective, orally bioavailable, and selective inhibitor of the PRMT5-MTA complex, with IC50 values of 3.6 nM and 20.5 nM for PRMT5-MTA and PRMT5, respectively. Navlimetostat can bind to the PRMT5-MTA complex with a KD value of 0.14 pM. Navlimetostat exhibits antitumor activity both in vitro and in vivo, making it a valuable tool for cancer research.
| 动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
1.Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.2022 Feb 10;65(3):1749-1766.
| 分子式 C23H18ClFN6O2 |
分子量 464.89 |
CAS号 2630904-45-7 |
储存方式 -20°C |
| 溶剂(常温) |
DMSO 93 mg/mL |
Water Insoluble |
Ethanol 93 mg/mL |
体内溶解度
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们